Navigation Links
Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
Date:6/25/2009

- Insmed to Evaluate Potential Initiation of Phase II Trial for IPLEX(TM) in MMD Patients with Severe Insulin Resistance -

RICHMOND, Va., June 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX(TM) (mecasermin rinfabate) in patients with myotonic muscular dystrophy ("MMD"). The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S. enrolled 69 patients with MMD, for a six-month period. As this was an exploratory trial, a primary endpoint was not pre-defined. The trial explored measures of endurance, using the six-minute walk test, muscle function and strength, cognitive function, gastrointestinal function, pain, quality of life, insulin sensitivity, lipid metabolism, and safety and tolerability of IPLEX(TM).

The results of the trial indicated that IPLEX(TM) did not exhibit a statistically significant improvement in the functional measure of endurance by the six-minute walk test, muscle function, muscle strength, or quality of life in any of the tests utilized in this study. Based on the limited number of subjects enrolled with significant impairments in cognitive function, gastrointestinal function or pain, Insmed was unable to reach any conclusions regarding the effects of IPLEX(TM) on these endpoints.

IPLEX(TM) did, however, demonstrate improvements in standard measures of insulin sensitivity and reductions in fasting glucose, fasting insulin, cholesterol and triglycerides, which is consistent with the expected metabolic profile of insulin-like growth factor. Administration of IPLEX(TM) also resulted in anabolic effects of increased body mass index and higher levels of testosterone. The drug was well tolerated in MMD subjects and d
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed CEO Resigns Due to Health Concerns
2. Insmed Announces First Quarter 2009 Financial Results
3. Insmed Regains NASDAQ Compliance
4. Insmed to Host First Quarter 2009 Conference Call
5. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
6. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
7. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
8. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
9. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
11. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
(Date:5/28/2015)... , May 27, 2015 Research and ... "Animal Genetics Market by Products, by Testing services ... offering. The global animal genetics market is ... and grow at a CAGR of 8-9% during the ... market is mainly driven by increasing animal protein consumption, ...
(Date:5/28/2015)... , May 27, 2015 Research and ... Jain PharmaBiotech,s new report "Neuroprotection - Drugs, ... This report describes the role of neuroprotection ... of the nervous system as well as in ... of the underlying mechanisms of damage to neural ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation (the ... has received commitments from two institutional healthcare investors to ... Company,s common stock in an at-the-market registered direct offering ... common stock. The Company entered into a ... the Company agreed to sell an aggregate of 3,000,000 ...
Breaking Biology Technology:Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3
... Pharmaceuticals to develop drug candidate for prevention and ... function in kidney transplantation, LONDON, June 25 ... that the U.S. Food and Drug Administration (FDA) ... Drug,application (IND) for an siRNA therapeutic product based ...
... EAST SETAUKET, N.Y., June 25 Lixte,Biotechnology Holdings ... Institute of Neurological Disorders and Stroke (NINDS), National,Institutes ... extended,their Cooperative Research and Development Agreement (CRADA) to ... CRADA, initiated in March,2006 was extended through September ...
... makers of the ground-breaking hemostatic agent, WoundStat™ – today announced that ... its quality system for design, development, production and sales of medical ... 2007 , ... BETHESDA, Md. (Business Wire EON) ...
Cached Biology Technology:FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry 2FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry 3Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 2Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 3 TraumaCure Receives Prestigious ISO 13485 Certification 2
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... teams of scientists, including three researchers from UC Riverside, ... roughly 100 million years before the Great Oxidation Event ... when most geoscientists think atmospheric oxygen rose sharply from ... life that followed almost two billion years later. ...
... horticulture research on high tunnels, grafting vegetables ... Society for Horticultural Science (ASHS) has published ... from the 2007 ASHS Annual Conference in ... of horticulture presentations by world-class scientists, innovative ...
... Branford, September 27, 2007 454 Life Sciences, ... the University of Illinois at Urbana-Champaign today announced ... behavior in wasps. Using the companys Genome Sequencer ... brains of wasps and correlated different expression patterns ...
Cached Biology News:Researchers detect hint of oxygen 50 to 100 million years earlier than first believed 2HortTalks, a valuable scientific resource 2454 Sequencing uncovers a genetic basis for different social behaviors in wasp 2
... Service includes 1. Scanning of gel(s) ... High-sensitive tryptic in-gel digestion and peptide ... MALDI-MS 5. Acquisition of PMF (Peptide ... ultraflex TOF/TOF) 6. Acquisition of PFF ...
... Nucleic acid hybridization Preparation Reconstitution: ... BSA, 50 mg ficoll and ... 5 ml of water yields ... molecular biology Density: 1.00 g/mL ...
... The ImageXpress 5000A automated cellular imaging and ... software system designed specifically for rapid acquisition ... throughput cell-based screening. ImageXpress is fast. ... resolution (1280 x 1024 pixels), with two ...
... The ProteinChip Antibody ... assay development and optimization ... evaluate antibody-antigen interactions. This ... and differentiation of multiple ...
Biology Products: